Adenosine Deaminase-Severe Combined Immunodeficiency Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major adenosine deaminase-severe combined immunodeficiency markets reached a value of US$ 5.8 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 11.3 Billion by 2034, exhibiting a growth rate (CAGR) of 6.24% during 2024-2034.
The adenosine deaminase-severe combined immunodeficiency market has been comprehensively analyzed in IMARC's new report titled "Adenosine Deaminase-Severe Combined Immunodeficiency Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Adenosine deaminase-severe combined immunodeficiency (ADA-SCID) is a rare inherited disorder characterized by a severely compromised immune system. This condition is caused by mutations in the adenosine deaminase gene that lead to a deficiency in the enzyme adenosine deaminase, which plays a critical part in the formation and function of immune cells, particularly T and B lymphocytes. Individuals suffering from ADA-SCID exhibit a range of severe symptoms due to their compromised immune systems. Recurrent and serious infections, often caused by bacteria, viruses, and fungi, are common. These infections can affect various organ systems and pose a substantial threat to the health and survival of the patient. Numerous other indications include failure to thrive, developmental delays, and immune-related complications. Diagnosing ADA-SCID involves clinical assessment, immunological testing, and genetic analysis. The healthcare provider might perform blood workups to reveal a marked depletion of T and B lymphocytes and functional tests to confirm the immune system's impaired responses.
The escalating cases of genetic conditions, causing mutations in the ADA gene, which lead to enzyme dysfunction and consequent immune system anomalies, are primarily driving the adenosine deaminase-severe combined immunodeficiency market. In addition to this, the inflating utilization of enzyme replacement therapy to combat the symptoms and manage the disorder is also creating a positive outlook for the market. Moreover, the widespread adoption of gene therapy, since it introduces corrected genes into cells to replace or amend the flawed genes underlying the condition, is further bolstering the market growth. Apart from this, the rising usage of bone marrow transplantation, a primary treatment modality that helps to restore a functional immune system, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of adoptive T-cell therapies, aimed at infusing the patient with functional T cells, thereby offering long-lasting immune restoration and improving the quality of life, is also augmenting the market growth. Furthermore, the increasing demand for non-conditioned stem cell transplantation procedures, since they ensure minimal side effects, shorter hospital stay as well as preservation of a patient's future ability to have children, is expected to drive the adenosine deaminase-severe combined immunodeficiency market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the adenosine deaminase-severe combined immunodeficiency market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for adenosine deaminase-severe combined immunodeficiency and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the adenosine deaminase-severe combined immunodeficiency market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the adenosine deaminase-severe combined immunodeficiency market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the adenosine deaminase-severe combined immunodeficiency market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current adenosine deaminase-severe combined immunodeficiency marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the adenosine deaminase-severe combined immunodeficiency market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the adenosine deaminase-severe combined immunodeficiency market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the adenosine deaminase-severe combined immunodeficiency market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of adenosine deaminase-severe combined immunodeficiency across the seven major markets?
What is the number of prevalent cases (2018-2034) of adenosine deaminase-severe combined immunodeficiency by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of adenosine deaminase-severe combined immunodeficiency by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with adenosine deaminase-severe combined immunodeficiency across the seven major markets?
What is the size of the adenosine deaminase-severe combined immunodeficiency patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of adenosine deaminase-severe combined immunodeficiency?
What will be the growth rate of patients across the seven major markets?
Adenosine Deaminase-Severe Combined Immunodeficiency: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for adenosine deaminase-severe combined immunodeficiency drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the adenosine deaminase-severe combined immunodeficiency market?
What are the key regulatory events related to the adenosine deaminase-severe combined immunodeficiency market?
What is the structure of clinical trial landscape by status related to the adenosine deaminase-severe combined immunodeficiency market?
What is the structure of clinical trial landscape by phase related to the adenosine deaminase-severe combined immunodeficiency market?
What is the structure of clinical trial landscape by route of administration related to the adenosine deaminase-severe combined immunodeficiency market?
The adenosine deaminase-severe combined immunodeficiency market has been comprehensively analyzed in IMARC's new report titled "Adenosine Deaminase-Severe Combined Immunodeficiency Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Adenosine deaminase-severe combined immunodeficiency (ADA-SCID) is a rare inherited disorder characterized by a severely compromised immune system. This condition is caused by mutations in the adenosine deaminase gene that lead to a deficiency in the enzyme adenosine deaminase, which plays a critical part in the formation and function of immune cells, particularly T and B lymphocytes. Individuals suffering from ADA-SCID exhibit a range of severe symptoms due to their compromised immune systems. Recurrent and serious infections, often caused by bacteria, viruses, and fungi, are common. These infections can affect various organ systems and pose a substantial threat to the health and survival of the patient. Numerous other indications include failure to thrive, developmental delays, and immune-related complications. Diagnosing ADA-SCID involves clinical assessment, immunological testing, and genetic analysis. The healthcare provider might perform blood workups to reveal a marked depletion of T and B lymphocytes and functional tests to confirm the immune system's impaired responses.
The escalating cases of genetic conditions, causing mutations in the ADA gene, which lead to enzyme dysfunction and consequent immune system anomalies, are primarily driving the adenosine deaminase-severe combined immunodeficiency market. In addition to this, the inflating utilization of enzyme replacement therapy to combat the symptoms and manage the disorder is also creating a positive outlook for the market. Moreover, the widespread adoption of gene therapy, since it introduces corrected genes into cells to replace or amend the flawed genes underlying the condition, is further bolstering the market growth. Apart from this, the rising usage of bone marrow transplantation, a primary treatment modality that helps to restore a functional immune system, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of adoptive T-cell therapies, aimed at infusing the patient with functional T cells, thereby offering long-lasting immune restoration and improving the quality of life, is also augmenting the market growth. Furthermore, the increasing demand for non-conditioned stem cell transplantation procedures, since they ensure minimal side effects, shorter hospital stay as well as preservation of a patient's future ability to have children, is expected to drive the adenosine deaminase-severe combined immunodeficiency market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the adenosine deaminase-severe combined immunodeficiency market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for adenosine deaminase-severe combined immunodeficiency and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the adenosine deaminase-severe combined immunodeficiency market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the adenosine deaminase-severe combined immunodeficiency market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the adenosine deaminase-severe combined immunodeficiency market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current adenosine deaminase-severe combined immunodeficiency marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the adenosine deaminase-severe combined immunodeficiency market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the adenosine deaminase-severe combined immunodeficiency market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the adenosine deaminase-severe combined immunodeficiency market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of adenosine deaminase-severe combined immunodeficiency across the seven major markets?
What is the number of prevalent cases (2018-2034) of adenosine deaminase-severe combined immunodeficiency by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of adenosine deaminase-severe combined immunodeficiency by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with adenosine deaminase-severe combined immunodeficiency across the seven major markets?
What is the size of the adenosine deaminase-severe combined immunodeficiency patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of adenosine deaminase-severe combined immunodeficiency?
What will be the growth rate of patients across the seven major markets?
Adenosine Deaminase-Severe Combined Immunodeficiency: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for adenosine deaminase-severe combined immunodeficiency drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the adenosine deaminase-severe combined immunodeficiency market?
What are the key regulatory events related to the adenosine deaminase-severe combined immunodeficiency market?
What is the structure of clinical trial landscape by status related to the adenosine deaminase-severe combined immunodeficiency market?
What is the structure of clinical trial landscape by phase related to the adenosine deaminase-severe combined immunodeficiency market?
What is the structure of clinical trial landscape by route of administration related to the adenosine deaminase-severe combined immunodeficiency market?
?1 Preface
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 ADENOSINE DEAMINASE-SEVERE COMBINED IMMUNODEFICIENCY - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 ADENOSINE DEAMINASE-SEVERE COMBINED IMMUNODEFICIENCY - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 ADENOSINE DEAMINASE-SEVERE COMBINED IMMUNODEFICIENCY - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 ADENOSINE DEAMINASE-SEVERE COMBINED IMMUNODEFICIENCY - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 ADENOSINE DEAMINASE-SEVERE COMBINED IMMUNODEFICIENCY - UNMET NEEDS
10 ADENOSINE DEAMINASE-SEVERE COMBINED IMMUNODEFICIENCY - KEY ENDPOINTS OF TREATMENT
11 ADENOSINE DEAMINASE-SEVERE COMBINED IMMUNODEFICIENCY - MARKETED PRODUCTS
11.1 List of Adenosine Deaminase-Severe Combined Immunodeficiency Marketed Drugs Across the Top 7 Markets
11.1.1 Revcovi (Elapegademase-Lvlr) - Leadiant Biosciences
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Adagen (Pegademase Bovine) - ENZON Pharmaceuticals
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Strimvelis- Orchard Therapeutics
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 ADENOSINE DEAMINASE-SEVERE COMBINED IMMUNODEFICIENCY - PIPELINE DRUGS
12.1 List of Adenosine Deaminase-Severe Combined Immunodeficiency Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. ADENOSINE DEAMINASE-SEVERE COMBINED IMMUNODEFICIENCY - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. ADENOSINE DEAMINASE-SEVERE COMBINED IMMUNODEFICIENCY – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 ADENOSINE DEAMINASE-SEVERE COMBINED IMMUNODEFICIENCY - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Adenosine Deaminase-Severe Combined Immunodeficiency - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Adenosine Deaminase-Severe Combined Immunodeficiency - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Adenosine Deaminase-Severe Combined Immunodeficiency - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Adenosine Deaminase-Severe Combined Immunodeficiency - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Adenosine Deaminase-Severe Combined Immunodeficiency - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Adenosine Deaminase-Severe Combined Immunodeficiency - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Adenosine Deaminase-Severe Combined Immunodeficiency - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Adenosine Deaminase-Severe Combined Immunodeficiency - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Adenosine Deaminase-Severe Combined Immunodeficiency - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Adenosine Deaminase-Severe Combined Immunodeficiency - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Adenosine Deaminase-Severe Combined Immunodeficiency - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Adenosine Deaminase-Severe Combined Immunodeficiency - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Adenosine Deaminase-Severe Combined Immunodeficiency - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Adenosine Deaminase-Severe Combined Immunodeficiency - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Adenosine Deaminase-Severe Combined Immunodeficiency - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Adenosine Deaminase-Severe Combined Immunodeficiency - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Adenosine Deaminase-Severe Combined Immunodeficiency - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Adenosine Deaminase-Severe Combined Immunodeficiency - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Adenosine Deaminase-Severe Combined Immunodeficiency - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Adenosine Deaminase-Severe Combined Immunodeficiency - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Adenosine Deaminase-Severe Combined Immunodeficiency - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Adenosine Deaminase-Severe Combined Immunodeficiency - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Adenosine Deaminase-Severe Combined Immunodeficiency - Access and Reimbursement Overview
16 ADENOSINE DEAMINASE-SEVERE COMBINED IMMUNODEFICIENCY - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 ADENOSINE DEAMINASE-SEVERE COMBINED IMMUNODEFICIENCY MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 ADENOSINE DEAMINASE-SEVERE COMBINED IMMUNODEFICIENCY MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 ADENOSINE DEAMINASE-SEVERE COMBINED IMMUNODEFICIENCY - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 ADENOSINE DEAMINASE-SEVERE COMBINED IMMUNODEFICIENCY - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 ADENOSINE DEAMINASE-SEVERE COMBINED IMMUNODEFICIENCY - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 ADENOSINE DEAMINASE-SEVERE COMBINED IMMUNODEFICIENCY - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 ADENOSINE DEAMINASE-SEVERE COMBINED IMMUNODEFICIENCY - UNMET NEEDS
10 ADENOSINE DEAMINASE-SEVERE COMBINED IMMUNODEFICIENCY - KEY ENDPOINTS OF TREATMENT
11 ADENOSINE DEAMINASE-SEVERE COMBINED IMMUNODEFICIENCY - MARKETED PRODUCTS
11.1 List of Adenosine Deaminase-Severe Combined Immunodeficiency Marketed Drugs Across the Top 7 Markets
11.1.1 Revcovi (Elapegademase-Lvlr) - Leadiant Biosciences
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Adagen (Pegademase Bovine) - ENZON Pharmaceuticals
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Strimvelis- Orchard Therapeutics
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 ADENOSINE DEAMINASE-SEVERE COMBINED IMMUNODEFICIENCY - PIPELINE DRUGS
12.1 List of Adenosine Deaminase-Severe Combined Immunodeficiency Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. ADENOSINE DEAMINASE-SEVERE COMBINED IMMUNODEFICIENCY - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. ADENOSINE DEAMINASE-SEVERE COMBINED IMMUNODEFICIENCY – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 ADENOSINE DEAMINASE-SEVERE COMBINED IMMUNODEFICIENCY - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Adenosine Deaminase-Severe Combined Immunodeficiency - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Adenosine Deaminase-Severe Combined Immunodeficiency - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Adenosine Deaminase-Severe Combined Immunodeficiency - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Adenosine Deaminase-Severe Combined Immunodeficiency - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Adenosine Deaminase-Severe Combined Immunodeficiency - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Adenosine Deaminase-Severe Combined Immunodeficiency - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Adenosine Deaminase-Severe Combined Immunodeficiency - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Adenosine Deaminase-Severe Combined Immunodeficiency - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Adenosine Deaminase-Severe Combined Immunodeficiency - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Adenosine Deaminase-Severe Combined Immunodeficiency - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Adenosine Deaminase-Severe Combined Immunodeficiency - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Adenosine Deaminase-Severe Combined Immunodeficiency - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Adenosine Deaminase-Severe Combined Immunodeficiency - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Adenosine Deaminase-Severe Combined Immunodeficiency - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Adenosine Deaminase-Severe Combined Immunodeficiency - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Adenosine Deaminase-Severe Combined Immunodeficiency - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Adenosine Deaminase-Severe Combined Immunodeficiency - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Adenosine Deaminase-Severe Combined Immunodeficiency - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Adenosine Deaminase-Severe Combined Immunodeficiency - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Adenosine Deaminase-Severe Combined Immunodeficiency - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Adenosine Deaminase-Severe Combined Immunodeficiency - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Adenosine Deaminase-Severe Combined Immunodeficiency - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Adenosine Deaminase-Severe Combined Immunodeficiency - Access and Reimbursement Overview
16 ADENOSINE DEAMINASE-SEVERE COMBINED IMMUNODEFICIENCY - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 ADENOSINE DEAMINASE-SEVERE COMBINED IMMUNODEFICIENCY MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 ADENOSINE DEAMINASE-SEVERE COMBINED IMMUNODEFICIENCY MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
